Merck's HIV Isentress (a generic raltegravir) may have been a big success across many markets, but in India the third generation oral anti-HIV drug may be short of its mark.
Domestic pharma giant Cipla has taken the route of applying for a "voluntary license" for the drug to Merck saying it is not reaching needy patients in India and is prices exorbitantly, reports CNBC-TV18 quoting PharmAsia.
At 09:41 am Cipla was quoting at Rs 318.55, down Rs 2.25, or 0.70%. The share touched an intraday high of Rs 323.80 and an intraday low of Rs 317.70.
It was trading with volumes of 11,307 shares, compared to its 5-day average of 219,469 shares, a decrease of -94.85%. It was trading with volumes of 11,307 shares, compared to its 30-day average of 260,026 shares, a decrease of -95.65%. In the previous trading session, the share closed down 0.08% or Rs 0.25 at Rs 320.80.
The company touched its 52-week high Rs 380.80 and 52-week low Rs 286.10 on 04 Jan, 2011 and 21 Mar, 2011, respectively. Currently, it is trading -16.35% below its 52-week high and 11.34% above its 52-week low.
DEEPAK KUMAR
PGDM 2ND SEM
Domestic pharma giant Cipla has taken the route of applying for a "voluntary license" for the drug to Merck saying it is not reaching needy patients in India and is prices exorbitantly, reports CNBC-TV18 quoting PharmAsia.
At 09:41 am Cipla was quoting at Rs 318.55, down Rs 2.25, or 0.70%. The share touched an intraday high of Rs 323.80 and an intraday low of Rs 317.70.
It was trading with volumes of 11,307 shares, compared to its 5-day average of 219,469 shares, a decrease of -94.85%. It was trading with volumes of 11,307 shares, compared to its 30-day average of 260,026 shares, a decrease of -95.65%. In the previous trading session, the share closed down 0.08% or Rs 0.25 at Rs 320.80.
The company touched its 52-week high Rs 380.80 and 52-week low Rs 286.10 on 04 Jan, 2011 and 21 Mar, 2011, respectively. Currently, it is trading -16.35% below its 52-week high and 11.34% above its 52-week low.
DEEPAK KUMAR
PGDM 2ND SEM
No comments:
Post a Comment